Clinical trials: Advanced Solid Cancer
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Advanced and/or Metastatic Solid Tumours
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to determine MTD and preliminary…
- Trial name
- POTENTIA (NCT04839991)
- Testing
- CB307
- Where
- 20 sites in United States, Netherlands and 2 more
- Volunteers
- 70 people
- Sponsor
- Crescendo Biologics Ltd.
Malignant Solid Tumor
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102.
- Trial name
- NCT01457118
- Testing
- NKTR-102 145 mg/m2, NKTR-102 120 mg/m2, NKTR-102 95 mg/m2
- Where
- 7 sites in United States, Belgium
- Volunteers
- 27 people
- Sponsor
- Nektar Therapeutics
Advanced Solid Tumors, Metastatic Solid Tumors
A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
This study is to assess the safety, tolerability and pharmacokinetics of single dose and multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with advanced or metastatic solid tumors.
- Trial name
- NCT01847118
- Testing
- Sevacizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Solid Tumor Cancer, Castration Resistant Metastatic Prostate Cancer
ITR-251 in Patients With Advanced Solid Tumors
This is an open-label, Phase I/Ib trial including an initial dose-escalation phase in patients with advanced solid tumors and a dose-expansion phase at recommended phase 2 dose (RP2D) in combination with Androgen Receptor Pathway…
- Trial name
- STRIVE-251 (NCT07870096)
- Testing
- ITR-251, ITR-251 at RP2D, ARPI therapy
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- ITERIA BIOPHARMA, S.L.
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic solid tumors (excluding primary brain tumors)…
- Trial name
- NCT04770246
- Testing
- TAS-117
- Where
- 8 sites in United States, Austria and 2 more
- Volunteers
- 17 people
- Sponsor
- Taiho Oncology, Inc.
Physiological Effects of Drugs, Neoplasms by Histologic Type
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
SHR-1603-I-101 is an single-arm, open-label, dose finding phase I clinical trial of SHR-1603 in subjects with advanced solid tumor or relapsed/refractory malignant lymphoid diseases.
- Conditions
- Physiological Effects of Drugs, Neoplasms by Histologic Type, Lymphoma, Hematologic Neoplasms
- Trial name
- NCT03722186
- Testing
- SHR-1603
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
The primary objective is to determine the safety and tolerability of SH3809 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3809 in solid tumors.
- Trial name
- NCT04843033
- Testing
- SH3809 tablet
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Advanced Solid Tumors
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.
- Trial name
- NCT01469052
- Testing
- AG-013736
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Solid Tumor, Unspecified, Adult
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
This proposal is a phase I, open-label study of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in patients with recurrent or metastatic, fibroblast activation protein-positive solid tumors.
- Trial name
- NCT05723640
- Testing
- 177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004 Injection group 2 radionuclide therapy, 177Lu-LNC1004 Injection group 3 radionuclide therapy
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
Hedgehog Pathway, Smoothened
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
- Conditions
- Hedgehog Pathway, Smoothened, Basal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS)
- Trial name
- NCT00670189
- Testing
- BMS-833923 (XL139)
- Where
- 3 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer
RATIONALE: A computer-based survey and communication aid may help physicians and patients to communicate better and help make treatment decisions easier.
- Trial name
- NCT00244868
- Testing
- counseling intervention, educational intervention
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Fox Chase Cancer Center
Urothelial Carcinoma, Advanced Solid Tumors
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
This multicenter, prospective phase II clinical trial aims to evaluate the efficacy and safety of medical compression stockings in preventing peripheral neuropathy induced by antibody-drug conjugates (ADCs) containing monomethyl…
- Conditions
- Urothelial Carcinoma, Advanced Solid Tumors, Chemotherapy-Induced Peripheral Neuropathy, Antibody-drug Conjugates
- Trial name
- NCT07164950
- Testing
- Medical-grade compression stocking
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sheng Zhang
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating patients with advanced…
- Trial name
- NCT00390117
- Testing
- CDKI AT7519, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Advanced Solid Tumors
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
An open-label phase I clinical study,which enrolled subjects with advanced solid tumors who have failed to respond to adequate standard therapies or have no available effective standard therapy.
- Trial name
- NCT07446816
- Testing
- Hemay181
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Solid Tumor
Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.
- Trial name
- NCT05547906
- Testing
- ASCA101
- Where
- 2 sites in United States, South Korea
- Volunteers
- 18 people
- Sponsor
- MetaFines
Solid Tumor
A Study of ASP1012 in Adults With Solid Tumors
ASP1012 is a type of virus called an oncolytic virus which is used to treat some cancers. ASP1012 was changed in a laboratory to infect and kill cancer cells, leaving healthy cells alone.
- Trial name
- NCT06171178
- Testing
- ASP1012, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Solid Tumor
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
The primary objective of this study is to identify a safe and tolerated dose and schedule of the orally administered PLK4 inhibitor RP-1664.
- Trial name
- NCT06232408
- Testing
- RP-1664
- Where
- 5 sites in United States, Denmark
- Volunteers
- 29 people
- Sponsor
- Repare Therapeutics
Neoplasms
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
The main objective of the dose-escalation part of the trial is to determine the safety and tolerability, and to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose (RP2D) of BI 754091 on the basis of patients…
- Trial name
- NCT02952248
- Testing
- BI 754091
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.